Bacteria News and Research

RSS

New substance to tackle drug resistant tuberculosis

This year's World Health Day focuses on the growing threat of potentially deadly infections developing resistance to antimicrobial drugs - especially to antibiotics. On this occasion, the European Commission is presenting the promising results of two EU-funded international research projects which provide new hopes to help and treat people.

8 Apr 2011

Hospira focuses on clinical surveillance systems to help reduce antimicrobial resistance

As part of World Health Day 2011, the World Health Organization is calling on policy makers, providers, the public and the healthcare industry to take action to combat the serious health threat of antimicrobial resistance.

8 Apr 2011

Bruker receives Health Canada approval for IVD MALDI Biotyper

At the 2011 Annual Meeting of the Canadian Association for Clinical Microbiology and Infectious Diseases, the companies i2A Canada and Bruker Ltd. announced together that they have met the relevant Health Products and Food Branch of Health Canada regulations for the Bruker IVD MALDI Biotyper, and that this product is now available for sale as a Class 1 Medical Device to all clinical microbiology sites in Canada.

8 Apr 2011

IDSA develops plans to combat deadly antibiotic-resistant 'super bugs'

To head off a health care disaster, the Infectious Diseases Society of America has developed a plan to combat deadly antibiotic-resistant "super bugs" and is rolling out the multi-pronged plan today, on World Health Day 2011.

8 Apr 2011

Scarab Genomics, CellMed enter agreement for Clean Genome E. coli Technology

Scarab Genomics announced a strategic agreement today with CellMed AG, a BTG International group company, in which CellMed AG will use Scarab Genomics' Clean Genome E. coli Technology in a new product development in the life science field.

7 Apr 2011

New CDC guidelines to reduce risk of catheter-associated infections in the U.S.

The CDC has announced new guidelines to reduce the risk of catheter-associated infections in the United States. The guidelines now designate treatment with chlorhexidine gluconate-impregnated sponge as a category 1B recommendation exclusively based on evidence related to BIOPATCH® Protective Disk with CHG.

7 Apr 2011

Novel strategy to build molecular probes may lead to development of new cancer drugs

Chemical engineers at UC Santa Barbara expect that their new process to create molecular probes may eventually result in the development of new drugs to treat cancer and other illnesses.

7 Apr 2011

Empire implements AGA, ACG guidelines for evaluation and management of dyspepsia and PUD

Empire BlueCross BlueShield today announced an initiative to inform and educate physicians and consumers about important findings from the American Gastroenterological Association (AGA) and the American College of Gastroenterology (ACG) related to a little known but common infection that is a precursor to serious stomach ailments.

7 Apr 2011

Quest Diagnostics Simplexa molecular test receives bronze award for best new product

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa™ molecular test on the 3M™ Integrated Cycler was honored with a bronze award for best new science and medical diagnostic product during the 2011 Edison Awards gala ceremony last night in New York City.

From Quest Diagnostics 7 Apr 2011

Superbugs and antibiotic resistance

Health experts come together today (Thursday) to warn that a new form of superbug that gives bacteria the power to resist virtually all known antibiotics is spreading quickly, posing a global health disaster. It is called New Delhi metallobeta-lactamase, or NDM-1 for short. This enzyme destroys carbapenems, an important group of antibiotics used for difficult infections in hospitals, and has been found in a wide variety of bacterial types. British researchers last August reported that infections involving NDM-1 had been found in patients in Bangladesh, India, Pakistan and Britain.

6 Apr 2011

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Optimer Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID, in the United States.

6 Apr 2011

CIC microGUNE uses DNA stretching technique to detect illnesses

Making DNA sequences being passed through nanochannels a thousand times thinner than a human hair to the point that they take on the form of diminutive spaghetti.

6 Apr 2011

Scientists identify biological pathways that mediate IgA nephropathy

For the first time, researchers have found five regions in the human genome that increase susceptibility to immunoglobulin A nephropathy, a major cause of kidney failure worldwide - systematically identifying those that point to a tendency for IgA nephropathy, or a protection against it.

6 Apr 2011

Antimicrobial copper can effectively prevent MRSA in hospitals

A live broadcast from the University of Southampton today highlighted the effectiveness of antimicrobial copper in preventing the spread of antibiotic-resistant organisms, such as MRSA, in hospitals.

5 Apr 2011

Experts to discuss on healthcare-associated infection at SHEA Annual Meeting

A special media phone briefing with leading infectious disease scientists and healthcare-associated infection experts who will headline the 2011 Society for Healthcare Epidemiology of America's Annual Meeting

4 Apr 2011

Study finds increased carbapenem use in VA acute care health facilities over the last 5 years

A large, multi-year study of antibiotic use in Veterans Health Administration's acute care facilities demonstrates dramatically increased use of carbapenems, a powerful class of antibiotics, over the last five years.

4 Apr 2011

QIAGEN to acquire Cellestis

QIAGEN N.V. has reached an agreement to acquire Cellestis Limited for approximately A$341 million in cash, providing QIAGEN with access to a novel "pre-molecular" technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.

From QIAGEN Manchester Limited 4 Apr 2011

New ‘nanotech’ weapon against drug-resistant superbugs

Scientists at the Institute of Bioengineering and Nanotechnology (IBN) and IBM Research – Almaden have developed the first biodegradable polymer nanoparticles to combat drug-resistant superbugs, such as Methicillin-Resistant Staphylococcus aureus (MRSA). These nanoparticles can selectively kill the bacteria without destroying healthy red blood cells, and being biodegradable, have great potential to treat infectious diseases in the body. This was reported today in the leading scientific journal, Nature Chemistry [(2011) DOI: 10.1038/nchem.1012].

3 Apr 2011

The Economist examines factors contributing to antimicrobial resistance

"Antibiotic resistance has now become a costly and dangerous problem," The Economist writes in an article examining the factors that have contributed to the global rise of antibiotic resistant bacteria, ahead of next week's World Health Day dedicated to the issue.

2 Apr 2011

CDC reviews clinical data from patients treated with BIOPATCH Protective Disk with CHG

Ethicon, Inc., announced today that the CDC has reviewed clinical data from patients treated with BIOPATCH Protective Disk with CHG as part of its update to the 2002 guidelines for reducing risk of intravascular catheter-associated infections in the United States. In the new guidelines, use of a CHG sponge dressing is designated as a Category 1B recommendation.

2 Apr 2011